Study of Hepatocellular Carcinoma Detection Capability, Exposure Reduction Effect, and Contrast Dose of Low Tube Voltage CT with Iterative Reconstruction in Patients with Chronic Liver Disease

Study of Hepatocellular Carcinoma Detection Capability, Exposure Reduction Effect, and Contrast Dose of Low Tube Voltage CT with Iterative Reconstruction in Patients with Chronic Liver Disease - Study of HCC Detection Capability, Exposure Reduction Effect, and Contrast Dose of Low Tube Voltage CT with Iterative Reconstruction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011705

Enrollment

340

Registered

2013-09-20

Start date

2013-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic carcinoma

Interventions

The patients for whom multi-phase hepatographic CT is performed to diagnose hepatocellular carcinoma will be randomly allocated to the following protocol groups: (1) 120 kVp

SD(noise index) 10, 600 mgI/kg

Without IR (control group) (2) With IR, 80 kVp

SD 10

370 mgI/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Patients with chronic liver disease 2, Patients suspected of hepatocellular 3, carcinoma 4, Body weight of 65 kg or lower 5, Both inpatients and outpatients 6, Both men and women 7, Patients aged 20 years or older Patients who had been provided with ample explanation before participating in this clinical study, fully understood the content of the study, and submitted a written consent to voluntarily participate in the study

Exclusion criteria

Exclusion criteria: 1, Lesions with a size of 2 cm or smaller 2, Patient who have over 5 lesions 3, According to "Contraindications and relative contraindications of contrast media in study patients" 4, Pregnant or lactating women 5, Patients for whom the investigator or subinvestigator(s) judges their participation in the clinical trial to be inappropriate

Design outcomes

Primary

Measure	Time frame
Ability to detect hypervascular hepatocellular carcinoma	—

Countries

Japan

Contacts

Public ContactTomoaki Ichikawa

University of Yamanashi hospital Department of Radiology

ichikawa@yamanashi.ac.jp055-273-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026